Getting to grips with data quality issues through international neuroscience initiatives

Pierre Meulien, Executive Director of the Innovative Medicines Initiative (IMI)
IMI – Europe’s partnership for health

**IMI1: 2008-2013**

- €2 bn ($2.4 bn)
- 59 projects

**IMI2: 2014-2020**

- €3.3 bn ($4 bn)
- More ambitious
- More open
- Greater scope

**Partnership 2008 - 2020**

- €2.5 bn

**> €5 bn ($6 bn)**

**EFPIA**

**BIO 2019 • IT STARTS WITH ONE**
IMI – Ecosystem for innovative collaborations

IMI is a neutral platform where all involved in drug development can engage in open collaboration on shared challenges in areas of unmet medical needs.

All partners needed to find transformative solutions to reduce late stage attrition, speed patient access and improve health outcomes and find solutions for a sustainable healthcare system

Over 11 500 researchers from an international, cross-sector community

Regulators
HTA bodies
Payers
Healthcare practitioners
Academia
Public health bodies
Charities
SMEs
Pharma companies
Diagnostic companies
Other sectors (e.g. imaging, digital, medtech, …)
Patients

BIO 2019 • IT STARTS WITH ONE
Our Panelists

• Dr Emily Sena
  BMJ Open Science, & Postdoctoral Research Fellow, University of Edinburgh

• Dr Shai Silberberg
  Director of Research Quality, NIH National Institute of Neurological Disorders and Stroke (NINDS)

• Dr Thomas Steckler
  Associate Director, Bioresearch and Quality and Compliance, Quality Planning & Strategy, Animal Welfare Strategy Lead, Janssen Pharmaceutica NV, Johnson & Johnson